中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

22 records (took 0.024 seconds)

    METHOD FOR SEROLOGICAL DETECTION OF VIRAL ANTIGENS
    12.
    发明申请
    METHOD FOR SEROLOGICAL DETECTION OF VIRAL ANTIGENS 审中-公开

    公开(公告)号：US20190086412A1

    公开(公告)日：2019-03-21

    申请号：US16204580

    申请日：2018-11-29

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Ralf Bollhagen ,  Barbara Upmeier ,  Toralf Zarnt ,  Peter Muench ,  Manfred Ginter

    IPC: G01N33/576 ,  G01N33/53

    Abstract: The present disclosure relates to a method for detecting a core polypeptide of a hepatitis C virus (HCV) in a sample from a subject involving (a) contacting said sample with a base and with a surfactant having a cationic detergent, and (b) detecting a core polypeptide of the HCV in the sample. The present invention further relates to a method for pre-processing a sample from a subject for detection of HCV, involving contacting the sample with a base and with a surfactant having a cationic detergent; and to a pre-processing reagent for detecting HCV in a sample, having a base and a surfactant including a cationic detergent, wherein the surfactant also has a nonionic detergent. Moreover, the present disclosure further relates to kits, uses, and devices related to the methods disclosed.

    Recombinant Trypanosoma cruzi JL7 antigen variants and their use for detecting Chagas disease
    13.
    发明授权
    Recombinant Trypanosoma cruzi JL7 antigen variants and their use for detecting Chagas disease 有权

    公开(公告)号：US10228370B2

    公开(公告)日：2019-03-12

    申请号：US15587907

    申请日：2017-05-05

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Dieter Roessler ,  Barbara Upmeier ,  Toralf Zarnt

    IPC: G01N33/569 ,  C07K14/44 ,  G01N33/564

    Abstract: The invention concerns variants of JL7 antigens that are suitable for detecting antibodies against Trypanosoma cruzi (causing Chagas disease) in an isolated biological sample. These antigens comprise a JL7 specific amino acid sequence, said JL7 specific sequence consisting of two copies of SEQ ID NO. 2, wherein each of said two copies has an amino acid identity of at least 90% to SEQ ID NO.2 and wherein no further Trypanosoma cruzi specific amino acid sequences are present in said polypeptide. The invention also concerns a composition of polypeptides useful for the detection of antibodies against Trypanosoma cruzi that comprises the above characterized JL7 antigen along with at least one of T. cruzi polypeptides 1F8, Cruzipain, KMP-11 and PAR-2. Moreover, it relates to a method for producing JL7 antigen as well as to diagnostic methods for detecting T. cruzi antibodies using the JL7 polypeptide. In addition, the invention concerns a reagent kit comprising said JL7 polypeptides or composition of Trypanosoma cruzi polypeptides.

    HBV IMMUNOCOMPLEXES FOR RESPONSE PREDICTION AND THERAPY MONITORING OF CHRONIC HBV PATIENTS
    14.
    发明申请
    HBV IMMUNOCOMPLEXES FOR RESPONSE PREDICTION AND THERAPY MONITORING OF CHRONIC HBV PATIENTS 审中-公开
    乙型肝炎免疫组织化学疗法对慢性乙型肝炎病人的反应预测和治疗监测

    公开(公告)号：US20150192583A1

    公开(公告)日：2015-07-09

    申请号：US14462802

    申请日：2014-08-19

    Applicant: Roche Diagnostics Operations, Inc. ,  Academic Medical Center at the University of Amsterdam

    Inventor： Ursula Klause ,  Berthold Hipp ,  Veit Peter Grunert ,  Barbara Upmeier ,  Uri Lopatin ,  Annikki de Niet ,  Henk Reesink ,  Hans Zaaijer

    IPC: G01N33/569

    CPC classification number: G01N33/56983 ,  G01N33/564 ,  G01N33/5761 ,  G01N2333/02 ,  G01N2800/52

    Abstract: The present invention relates to a method for identifying a subject suffering from hepatitis B virus (HBV) infection as being susceptible to interferon treatment, said method comprising the steps of a) determining, in a sample of said subject, the amount of HBV immune complexes, b) comparing the amount of HBV immune complexes obtained in step a) to a reference value, and c) identifying a subject suffering from HBV infection as being susceptible to interferon treatment based on the result of the comparison made in step b). The present invention further relates to the use of the determination of the amount of HBV immune complexes in a sample from a subject suffering from HBV infection and of a detection agent for HBV immune complexes for identifying a subject suffering from HBV infection as being susceptible to interferon treatment. Furthermore, the present invention relates to a device and a kit allowing identifying a subject suffering from HBV infection as being susceptible to interferon treatment.

    Abstract translation: 本发明涉及用于鉴定患有乙型肝炎病毒（HBV）感染的受试者易于进行干扰素治疗的方法，所述方法包括以下步骤：a）在所述受试者的样品中测定HBV免疫复合物的量 b）将步骤a）中获得的HBV免疫复合物的量与参考值进行比较，以及c）根据步骤b）中进行的比较结果，鉴定患有HBV感染的受试者易于进行干扰素治疗。 本发明还涉及确定来自患有HBV感染的受试者的样品中的HBV免疫复合物的量和HBV免疫复合物的检测剂用于鉴定患有HBV感染的受试者对于干扰素敏感的用途的用途 治疗。 此外，本发明涉及允许将患有HBV感染的受试者识别为易于进行干扰素治疗的装置和试剂盒。

    Methods for reducing interferences
    16.
    发明授权
    Methods for reducing interferences 有权

    公开(公告)号：US11156610B2

    公开(公告)日：2021-10-26

    申请号：US15621280

    申请日：2017-06-13

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Barbara Upmeier ,  Toralf Zarnt ,  Johannes Polz

    IPC: G01N31/00 ,  G01N33/53 ,  G01N33/543 ,  G01N33/68

    Abstract: Described is a method for determining an analyte in a sample suspected to contain the analyte, by a) contacting the sample with a first and a second capture compound for the analyte, wherein the first and second capture compounds are non-identical capture compounds, and the capture compounds compete in binding to the analyte; b) contacting the capture compounds contacted with the sample with a specifier, wherein the specifier competes in binding to the capture compounds with the analyte; c) determining the amount of complexes having the specifier and a capture compound; and d) determining the analyte in a sample based on the result of step c). Also disclosed is a method for improving the specificity of an indirect immunoassay for determining an analyte, as well as kits, devices, and uses related to the methods.

    Analytical test management system and method
    18.
    发明授权
    Analytical test management system and method 有权

    公开(公告)号：US10101349B2

    公开(公告)日：2018-10-16

    申请号：US15249834

    申请日：2016-08-29

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Sascha Martin Antoni ,  Martin Burri ,  Werner Doeppen ,  Bernhard Eckert ,  Elke Faatz ,  Barbara Upmeier ,  Andreas Woeste ,  Dieter Roessler ,  Elena Pfaffenrot

    IPC: G01N35/00 ,  G01N35/10 ,  G05B19/042

    Abstract: A test management system is presented. The system comprises an analyzer to perform tests a sample according to a first set of instructions, a manager module connected to the analyzer, and a first order interface connected to the manager module. The manager module directs activity of the analyzer according to a second set of instructions. The first order interface receives an order for a first analytical test and a second analytical test and transmits the order to the manager module. If the order is for the first analytical test, the test manager module forwards the order directly to the analyzer and the sample is analyzed by the analyzer according to the first set of instructions. If the order is for the second analytical test, the manager module handles the order according to the second set of instructions and generates and transmits secondary test requests to the analyzer.

    METHODS FOR REDUCING INTERFERENCES
    20.
    发明申请
    METHODS FOR REDUCING INTERFERENCES 审中-公开

    公开(公告)号：US20180128825A1

    公开(公告)日：2018-05-10

    申请号：US15621280

    申请日：2017-06-13

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Barbara Upmeier ,  Toralf Zarnt ,  Johannes Polz

    IPC: G01N33/543 ,  G01N33/68

    CPC classification number: G01N33/54393 ,  G01N33/54306 ,  G01N33/6854 ,  G01N2800/26

    Abstract: The present invention relates to a method for determining an analyte in a sample suspected to comprise said analyte, comprising a) contacting with said sample at least a first and a second capture compound for said analyte, wherein said first and second capture compounds are non-identical capture compounds, and wherein said capture compounds compete in binding to said analyte; b) contacting said capture compounds contacted with said sample with a specifier, wherein said specifier competes in binding to said capture compounds with said analyte; c) determining the amount of complexes comprising said specifier and a capture compound; and d) determining said analyte in a sample based on the result of step c). The present invention further relates to a method for improving the specificity of an indirect immunoassay for determining an analyte, comprising replacing at least 10% of a capture compound by a non-identical capture compound; wherein the capture compound replaced competes in binding to said analyte with the capture compound introduced. The present invention further relates to kits, devices, and uses related to the aforementioned methods.

Patent Agency Ranking